Patent №
US 7,202,217
Granted
2007-04-10
Filed 1999
Owner
BETH ISREAL DEACONESS MEDICAL CENTER
Lab
—
AI components
1
hardware
Assignment
Recorded
Dataset
AIPD
2023_r1 edition
Application
09276868
The present invention provides both a method and means for regulating angiogenesis within living cells, tissues, and organs in-situ. The regulation is performed using native PR-39 peptide or one of its shorter-length homologs, for direct interaction with the α7 subunit of such proteasomes as one present in the cytoplasm of viable cells. The result of PR-39 peptide interaction with proteasomes is a decrease in the intracellular degradation of active peptides such as HIF-1α and a consequential stimulation of angiogenesis in-situ.
AI classification
Ownership
BETH ISREAL DEACONESS MEDICAL CENTER
assignment · 101180298
Assignors
SIMONS, MICHAEL, GAO, YOUHE
On an employer assignment, the assignors are typically the inventors.